DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more



Usage of granulocyte colony-stimulating factor every 2 days is clinically useful and cost-effective for febrile neutropenia during early courses of chemotherapy.

Author(s): Yakushijin Y, Shikata H, Takaoka I, Horikawa T, Takeuchi K, Yamanouchi J, Azuma T, Narumi H, Hato T, Yasukawa M

Affiliation(s): Cancer Center of Ehime University Hospital, Ehime University Graduate School of Medicine, Shitsukawa, Toon, Ehime 7910295, Japan. yoshiyak@m.ehime-u.ac.jp

Publication date & source: 2011-04, Int J Clin Oncol., 16(2):118-24. Epub 2010 Oct 6.

Publication type: Clinical Trial; Randomized Controlled Trial

BACKGROUND: In order to analyze the clinical activity and cost-effectiveness of granulocyte colony-stimulating factors (G-CSF), the prophylactic usage of G-CSF in patients treated with a single chemotherapy regimen during early courses was prospectively evaluated. METHODS: Thirty patients with newly diagnosed non-Hodgkin lymphoma (NHL) treated with the first course of an R-CHOP regimen were enrolled randomly. After treatment with the first course of chemotherapy, a daily dose of G-CSF (lenograstim, 100 mug) was administered to half (15 cases) of the patients, and a dose of G-CSF (100 mug) was administered every other day to the other half of the patients when leukocytopenia (<1.5 x 10(9)/L) and/or neutropenia (<0.5 x 10(9)/L) occurred. Changes in leukocyte and neutrophil counts, prophylaxis, febrile neutropenia (FN) events, and cost performance between the two groups were analyzed. RESULTS: No significant difference between the two groups was observed in recoveries of leukocyte and neutrophil counts and evidence of FN. The only difference was the total cost of G-CSF. CONCLUSION: We concluded that every-other-day use of G-CSF was as clinically effective for the prophylaxis of FN as the daily use of G-CSF, and economically speaking, the administration of G-CSF every other day should be more beneficial for patients with NHL during early courses of R-CHOP chemotherapy.

Page last updated: 2011-12-09

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017